objective To determine the frequency of therapeutic failure among patients with acute and subacute brucellosis and to explore the predictors of failure.
Introduction
Brucellosis is the most common zoonotic infection. Globally, more than 500 000 new cases occur annually [1] . The prevalence is highest in the countries of the Mediterranean Sea basin, hence it is also known as Mediterranean fever [2] . In Egypt, a seroprevalence rate of approximately 1.3% exists in Assiut governorate [3] . The control program for brucellosis in Egypt includes vaccination of animals and slaughter of those infected (with positive serologic results). Egypt has mixed populations of cattle, sheep, and goats. The most frequent Brucella species is Brucella abortus followed by Brucella melitensis [4, 5] . Infected domestic animals -mainly cattle, sheep, goats and swine -are the source of infection in humans. Infection can be acquired by humans through direct contact with diseased animals or by consumption of contaminated animal products [6] . The presentation includes subclinical, acute and subacute, localised, relapsing and chronic forms [7] . The diagnosis of brucellosis is confirmed when compatible clinical manifestations are associated with at least a four-fold rise of Brucella antibody titre between acute and convalescent sera obtained at least 14 days apart measured by standard agglutination test (SAT). The diagnosis is probable when compatible clinical manifestations are associated with a single SAT antibody titre of at least 1:160 [8] .
Monotherapies are characterised by high rates of relapse; therefore a combination therapy of two drugs is used. Doxycycline (200 mg daily) plus rifampin (600-900 mg daily) for 6 weeks is the standard-of-care therapy [9] , which has a rate of 11-17% of therapeutic failure [10] . Doxycycline is absorbed in the proximal duodenum after being solubilised by gastric acidity [11] . Brucella isolates are considered susceptible to the WHO-recommended therapy which includes doxycycline and rifampin; only sporadic cases of antibiotic resistance were reported [12, 13] .
After infection with Brucella, the first line of defense is phagocytosis by cells (neutrophils, macrophages and dendritic cells, and natural killer cells), secretion of cytokines and chemokines, and activation of the complement system [14] . Brucella evades the immune system to persist long enough to be transmitted [15] . In addition, after intracellular existence, Brucella avoids the cellular destructive mechanism by several mechanisms [16] . Helminth infections may adversely affect the immune response to other infections, especially to those with intracellular pathogens [17, 18] . Hence, concomitant, endemic, infectious diseases may modulate the immune response to Brucella infection.
Our research hypothesis is that concomitant, endemic, infectious diseases and acid suppressive therapy can affect the therapeutic response to therapy for brucellosis. Our aim was to determine the frequency of therapeutic failure among patients with acute and subacute brucellosis and to explore the predictors of failure.
Patients and methods

Study design
This was a hospital-based, prospective cohort study conducted among patients attending the outpatient clinics and/or admitted to the inpatient sectors of the Department of Tropical Medicine and Gastroenterology and the Department of Internal Medicine in Assiut, Egypt, between May 2011 and January 2018.
Inclusion and exclusion criteria
We recruited 213 consecutive therapy-na€ ıve patients with acute (<3 months) and subacute (3 months to <12 months) brucellosis. Diagnosis relied on the presence of (i) contact with domestic animals (cattle, sheep, goats, and pigs) or their fresh products; (ii) compatible clinical manifestations (fever, chills, sweats, relative bradycardia, fatigue, arthralgia, myalgia, splenomegaly, hepatomegaly and lymphadenopathy) of <1 year duration; (iii) positive antibody titre (at least 1:160) by standard agglutination test SAT.
Patients younger than 18 years and pregnant women were excluded from the study. In addition, patients with clinical, radiological and/or microbiological evidence of TB, and those who received any antimicrobial therapy after the onset of illness were not included.
Methods
All participants underwent clinical evaluation, imaging studies and laboratory investigations. The use of acid suppressive, corticosteroid, immunosuppressant and antineoplastic therapies was considered significant if it lasted 2 weeks or longer during the period of treatment for acute and subacute brucellosis. Overweight was defined as a body mass index (BMI) of 25 kg/m 2 to <30 kg/m 2 , and obesity as a BMI of ≥30 kg/m 2 . Imaging studies included chest radiography and abdominal ultrasonography.
Laboratory investigations included estimation of fasting serum level of glucose and serum level of creatinine, complete blood count, liver chemistry, and testing for hepatitis B surface antigen (HBsAg), antibody to hepatitis C virus (anti-HCV Ab) and human immunodeficiency virus (anti-HIV Ab). Stool and urine microscopic examination for helminthic ova was carried out by an experienced parasitologist. After a minimum of 6-h overnight fasting, venous blood samples were collected. The same laboratory using standard methods was used for all laboratory investigations. Glucose intolerance was defined as fasting glucose level of >6.1 to <7 mmol/L, while DM was defined as fasting glucose level of 7 mmol/L or more. Liver cirrhosis was diagnosed based on clinical, imaging and laboratory findings.
In addition, tuberculin skin test (TST) was performed using purified protein derivative of the human strain of Mycobacterium tuberculosis (Vacsera, Egypt) for strict intradermal injection of five tuberculin units (0.1 mL). The injection was considered appropriate when a discrete, pale elevation of the skin (a wheal) 6-10 mm in diameter was detected. After 72 h, the results of TST were recorded; any induration of 10 mm or more was considered as a positive result [19] . Interferon-gamma release assay (IGRA) (QuantiFERON-TB Gold (QFT-G) test) Cellestis Ltd, Carnegie, Australia) was performed for the patients with positive TST. Whole blood was collected and incubated in blood collection tubes at 37°C for 24 h. After centrifugation of the tubes and removal of the plasma, measurement of interferon-gamma (INF-c) by enzyme-linked immunosorbent assay was performed. A tuberculin response percentage (based on INF-c response to the Mycobacterium tuberculosis antigen tube) of 30% or more was considered as a positive result. The diagnosis of latent tuberculosis infection (LTBI) relied on positive results of both TST and IGRA.
All participants received the WHO-recommended, standard of care therapy for acute and subacute brucellosis. Oral administration of doxycycline 200 mg/day and rifampin 900 mg/day, for 6 weeks, was confirmed. Rifampin was administered before breakfast to avoid the decrease in bioavailability by food [20] , while doxycycline was administered after breakfast to increase its solubility by the secreted gastric acid [11] . Each drug was produced by only one pharmaceutical company to avoid minor differences in bioavailability related to different production conditions. The study population was assessed clinically and by laboratory investigations weekly during the treatment period to monitor for any adverse effects.
Therapeutic failure was defined as persistence of the clinical manifestations of brucellosis at the end of therapy (after 6 weeks of treatment with doxycycline 200 mg daily and rifampin 900 mg daily), with a single, positive antibody titre within 6 months of ending the therapy [10, 21] .
Statistical analysis
Data were analysed using the Statistical Package for Social Sciences (IBM SPSS Statistics, version 22.0, release 22.0.0.0; IBM Corp, Armonk, NY, USA) for Microsoft Windows â (64-bit version). Results were expressed as mean AE standard deviation or frequency (percentage) as appropriate. The predictors of therapeutic failure of acute/subacute brucellosis among the study population were identified using univariate analyses (Yates' corrected chi-square test or Fischer's exact test). Multivariate analysis (binary logistic regression) was used to assess the independent effect of each predictor. Multivariate analysis included significant factors with P < 0.05 in the univariate analyses.
The software G*Power version 3.1.9.2 was used for a post hoc power analysis of the performed chi-square tests. An arbitrary effect size was chosen for the power analysis, which precisely was a Cohen's w statistic of 0.3. This value conventionally corresponds to a medium-sized effect. The power achieved was 0.84.
Ethical considerations
The study was approved by the Clinical Research Ethical Committee of Assiut Faculty of Medicine (IRB 00008717, approval date 30 March 2011) and carried out according to the code of ethics of the World Medical Association (Declaration of Helsinki). All the participants signed a consent certificate after discussing in detail with the investigators the certificate subjects and the study aim. Participants were clearly informed that refusing to participate in the study did not affect having full benefit of the available medical service. Data confidentiality was respected.
Results
Of 244 patients, 213 (87.3%) accepted to participate; 31 (12.7%) refused. Thus, the study population comprised 213 therapy-na€ ıve patients with acute and subacute brucellosis. The mean age of the study population was 39.8 AE 12.2 years; 64.8% of them were males. The clinical manifestations, therapeutic outcome and adverse effects according to the therapeutic outcome are shown in Table 1 . Therapeutic failure was detected among 35 (16.4%) of the patients. Fever was the most frequent clinical manifestation (95.8%). Regarding the adverse effects, no patient with therapeutic failure suffered skin rash, and oral candidiasis was absent among those with therapeutic response. After 6 weeks of treatment, 83.6% of the study population achieved therapeutic response. Adverse effects of antibiotic therapy for brucellosis were reported by 13.1% of the study population (14.3% of the patients with therapeutic failure and 12.9% among those with therapeutic response). Some patients had more than one adverse effect. The most frequent adverse effect was epigastric pain (10.8% of the study population). All adverse effects were tolerable and did not interfere with the proper administration of the antibiotics. Table 2 shows the demographic, clinical, imaging and laboratory characteristics of the patients with therapeutic failure vs. those with therapeutic response. The mean age of patients with therapeutic failure was After multivariate analysis of the factors associated with therapeutic failure, LTBI (OR 3.1, 95% CI, 1.9-24.6, P: 0.009), ascariasis (OR 2.6, 95% CI 1.5-17.9, P: 0.012), and the use of acid suppressive therapy (OR 2.1, 95% CI 1.2-19.5, P: 0.037) were the predictors of therapeutic failure among the study population with acute and subacute brucellosis (Table 3 ). Figure 1 shows a flow chart of the study cases with acute/subacute brucellosis.
Discussion
Brucellosis is considered as a serious zoonotic disease in our locality (with a prevalence of approximately 1.3% among the general population in Assiut Governorate) [3] , thus representing a major public health issue for the Egyptian medical authorities. Although dual antimicrobial therapy (doxycycline-rifampin) yields a fair response, it does not achieve an appropriate one, with a therapeutic failure rate as high as 17% due to the intracellular location of the bacteria [10] . The therapeutic failure rate in our study population was 16.4%, which is higher than the 13.2% reported among the Egyptian patients with acute/subacute brucellosis treated by dual therapy (doxycycline-rifampin) [22] . This may reflect the potential development of bacterial resistance to the standard of care therapy for brucellosis over time. A 16% therapeutic failure rate was reported among Spanish patients with brucellosis [23] . However, compared to our study population, 16% of those patients had previous brucellosis, while all our study patients were na€ ıve, raising concerns regarding antimicrobial resistance. In addition, more of their study participants were male (80% vs. 64.8%); and men may be more exposed to the infection than women due to their occupation.
To our knowledge, this is the first instance to determine the predictors of therapeutic failure among the patients with acute/subacute brucellosis treated by the WHO-recommended, standard of care therapy. It was found that LTBI, ascariasis, and the use of acid suppressive therapy were the predictors of therapeutic failure among the study population.
Brucella escapes immune destruction by creating Brucella-containing vacuole to allow for its replication [24] and inhibition of macrophage apoptosis to avoid the exposure to the hostile extracellular milieu [25] . In LTBI, mycobacteria evade the host immunity by dampening of macrophage functions through inhibition of the generation of antimycobacterial nitric oxide and reactive nitrogen intermediate [26] , disrupting the maturation of mycobacteria-containing phagosomes into phagolysosomes [27] , and inhibition of macrophage apoptosis limiting the extracellular exposure of mycobacteria to the immune cells [28] . A potential synergism may exist between the intracellular mycobacteria and Brucella in suppressing macrophage destructive function and apoptotic activity, providing more protection for both organisms against the antimicrobial therapy. This may explain the adverse effect of concomitant LTBI on acute/subacute brucellosis, leading to significantly lower therapeutic response to dual antibiotic therapy. Figure 1 Flow chart of the study cases with acute/subacute brucellosis. LTBI, latent tuberculosis infection.
Patients with helminth infections, including ascariasis, are in a state of chronic immune-activation producing an enhanced TH2 immune profile; through the release of inhibitory cytokines (interleukin-10 and transforming growth factor-beta), this profile leads to suppressed generation of TH1-type immune response, and consequently failure to induce adequate immune response to other infections, especially to the intracellular pathogens [18] . An enhanced TH2 immune profile was suggested by eosinophilia, elevated levels of immunoglobulin E, and mast cell activation, which are compatible with the enhanced cytokine response by type 2-T-helper cells [29] . This may be the link between ascariasis and the reduced therapeutic response of the intracellular pathogen, Brucella, to the antibiotic therapy.
The absorption of doxycycline occurs in the duodenum, where the pH is approximately 5-7. However, complete absorption of doxycycline requires the normal low pH in the stomach; doxycycline is less soluble at the pH of the duodenum and needs to dissolve in the acidic environment in the stomach first. The increase in gastric pH decreases the rate and extent of doxycycline absorption by as much as 50% [11] . Thus, the use of acid suppressive therapy among the study population with acute/ subacute brucellosis may have reduced the bioavailability of doxycycline, and consequently impaired the therapeutic response of brucellosis to antibiotic therapy. Separating the dose of acid suppressive therapy from that of the antimicrobial therapy did not show to minimise its negative impact on the bioavailability of doxycycline [11] .
The study lacks antibiotic susceptibility testing of Brucella before the initiation of treatment. Blood culture requires incubation for 6 weeks with a diagnostic yield of 40-90% in acute brucellosis [30] . In addition, brucellosis is one of the most common laboratory-transmitted infections; 2% of the cases are laboratory-acquired [31] . Serological diagnosis is reliable when brucellosis is suspected, especially in subacute brucellosis with variable yield of culture [32] . Also, determining the species of Brucella was not possible; polymerase chain reaction testing was not performed. Another limitation is that colonoscopic examination of the rectum was not performed to obtain specimens of the rectal mucosa to be examined for schistosomal ova; we relied on stool and urine microscopic examination. However, this is the first study to explore the predictors of the therapeutic failure among the patients with acute/subacute brucellosis.
In conclusion, the prevalence of therapeutic failure among the Egyptian patients with acute/subacute brucellosis is increasing. Predictors of therapeutic failure were LTBI, ascariasis, and the use of acid suppressive therapy. Any kind of acid suppressive therapy should be stopped before starting therapy for brucellosis and suspended until the end. Screening patients with brucellosis for LTBI and ascariasis and treating such infections before starting therapy for brucellosis would be preferable. Further studies with antibiotic susceptibility testing of Brucella for doxycycline and rifampin are recommended.
